KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Charles River Laboratories International (CRL) Revenue (2016 - 2025)

Charles River Laboratories International has reported Revenue over the past 17 years, most recently at $994.2 million for Q4 2025.

  • Quarterly results put Revenue at $994.2 million for Q4 2025, down 0.83% from a year ago — trailing twelve months through Dec 2025 was $4.0 billion (down 0.85% YoY), and the annual figure for FY2025 was $4.0 billion, down 0.85%.
  • Revenue for Q4 2025 was $994.2 million at Charles River Laboratories International, down from $1.0 billion in the prior quarter.
  • Over the last five years, Revenue for CRL hit a ceiling of $1.1 billion in Q4 2022 and a floor of $824.6 million in Q1 2021.
  • Median Revenue over the past 5 years was $1.0 billion (2024), compared with a mean of $985.6 million.
  • Biggest five-year swings in Revenue: skyrocketed 33.99% in 2021 and later dropped 7.85% in 2023.
  • Charles River Laboratories International's Revenue stood at $905.0 million in 2021, then increased by 21.52% to $1.1 billion in 2022, then dropped by 7.85% to $1.0 billion in 2023, then decreased by 1.08% to $1.0 billion in 2024, then decreased by 0.83% to $994.2 million in 2025.
  • The last three reported values for Revenue were $994.2 million (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025) per Business Quant data.